- Home
- TIC vs AZTA Comparison
TIC vs AZTA Comparison
Compare TIC & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIC
- AZTA
- Stock Information
- Founded
- TIC 1991
- AZTA 1978
- Country
- TIC United States
- AZTA United States
- Employees
- TIC N/A
- AZTA N/A
- Industry
- TIC
- AZTA Industrial Machinery/Components
- Sector
- TIC
- AZTA Technology
- Exchange
- TIC Nasdaq
- AZTA Nasdaq
- Market Cap
- TIC 1.5B
- AZTA 1.8B
- IPO Year
- TIC N/A
- AZTA 1995
- Fundamental
- Price
- TIC $10.91
- AZTA $29.64
- Analyst Decision
- TIC Hold
- AZTA Buy
- Analyst Count
- TIC 1
- AZTA 3
- Target Price
- TIC $11.50
- AZTA $50.67
- AVG Volume (30 Days)
- TIC 911.4K
- AZTA 703.4K
- Earning Date
- TIC 08-03-2025
- AZTA 08-05-2025
- Dividend Yield
- TIC N/A
- AZTA N/A
- EPS Growth
- TIC N/A
- AZTA N/A
- EPS
- TIC N/A
- AZTA N/A
- Revenue
- TIC $1,108,546,000.00
- AZTA $669,171,000.00
- Revenue This Year
- TIC $4.52
- AZTA N/A
- Revenue Next Year
- TIC $5.23
- AZTA $4.89
- P/E Ratio
- TIC N/A
- AZTA N/A
- Revenue Growth
- TIC 9.12
- AZTA 8.56
- 52 Week Low
- TIC $8.76
- AZTA $23.91
- 52 Week High
- TIC $14.28
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- TIC N/A
- AZTA 54.22
- Support Level
- TIC N/A
- AZTA $29.16
- Resistance Level
- TIC N/A
- AZTA $30.86
- Average True Range (ATR)
- TIC 0.00
- AZTA 1.18
- MACD
- TIC 0.00
- AZTA 0.13
- Stochastic Oscillator
- TIC 0.00
- AZTA 70.88
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.